Taltz ® (ixekizumab)

Taltz® (ixekizumab): What is the dosing regimen in axial spondyloarthritis?

160 mg at week 0, then 80 mg every 4 weeks.

UK_cFAQ_IXE306_Z3_DOSING_axSpA
UK_cFAQ_IXE306_Z3_DOSING_axSpA
en-GB

Ixekizumab Dosage Regimen in Radiographic and Non-radiographic Axial Spondyloarthritis

The recommended dose is 160 mg (two 80 mg injections) by subcutaneous injection at Week 0, followed by 80 mg every 4 weeks.1

Consideration should be given to discontinuing treatment in patients who have shown no response after 16 to 20 weeks of treatment.1

Some patients with initially partial response may subsequently improve with continued treatment beyond 20 weeks.1

No dose adjustment is required in elderly patients (≥ 65years).1

There is limited information in subjects aged ≥ 75 years.1

Ixekizumab has not been studied in patients with renal or hepatic impairment. No dose recommendations can be made.1

Method of Administration

Ixekizumab is for subcutaneous injection.1

  • Injection sites may be alternated.1
  • If possible, areas of the skin that show psoriasis should be avoided as injection sites.1

After proper training in subcutaneous injection technique, patients may self-inject ixekizumab if a healthcare professional determines that it is appropriate. However, the physician should ensure appropriate follow-up of patients. Comprehensive instructions for administration are given in the package leaflet.1

References

1Taltz [summary of product characteristics]. Eli Lilly and Company (Ireland) Limited, Ireland

Date of Last Review: June 17, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request